14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LSBK vs INTG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Lake Shore Bancorp, Inc. (LSBK) is the stronger overall head-to-head candidate over Intergroup Corporation (The) (INTG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). LSBK carries a Unified Composite Score of 57.1/100 (HOLD) at $18.90 (14.4x Forward P/E, 35.0% operating margin), whereas INTG carries 32.5/100 (SELL) at $41.48 (N/M Forward P/E, 16.1% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LSBK vs INTG. Trailing 12-month operating profitability (LSBK 35.0% vs INTG 16.1%) and valuation multiples (LSBK 14.4x vs INTG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Lodging value chain with $89.7M market capitalization and 16.1% operating margin.
OpEx & R&D Reinvestment13.0% of Rev ($9.6M)
90D Engineering Disclosures0 Published
Investor FAQ LSBK vs INTG Key Questions & Quantitative Answers
As of Nov 16, 2026, Lake Shore Bancorp, Inc. (LSBK) is the stronger overall head-to-head candidate over Intergroup Corporation (The) (INTG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). LSBK carries a Unified Composite Score of 57.1/100 (HOLD) at $18.90 (14.4x Forward P/E, 35.0% operating margin), whereas INTG carries 32.5/100 (SELL) at $41.48 (N/M Forward P/E, 16.1% operating margin). Technically, LSBK sits in a Markup phase (RSI 56.5, UNCLASSIFIED options structure) and INTG sits in a Markup phase (RSI 70.4, UNCLASSIFIED options structure).
INTG leads the Growth & Scale pillar: LSBK posts -0.6% YoY revenue growth and -2.9% YoY earnings growth on $30M TTM revenue (100.0% gross margin, 35.0% operating margin), compared with INTG at +13.3% YoY revenue growth and N/A YoY earnings growth on $74M TTM revenue (29.1% gross margin, 16.1% operating margin). On trailing 12-month operating scale, LSBK generates $30M in USD-normalized revenue versus $74M for INTG. In operating R&D and SG&A reinvestment, LSBK deploys 65.0% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 13.0% of Rev ($9.6M) (0 disclosures) for INTG.
LSBK screens cheaper on headline valuation multiples. LSBK trades at 14.4x Forward P/E, 16.6x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported cash flow margin), whereas INTG trades at N/M Forward P/E, 58.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (3.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LSBK (5.9% ROE) versus INTG (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, LSBK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.06β · 17% Vol realized risk). By comparison, INTG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.14β · 42% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.